Free Trial
NASDAQ:CLYM

Climb Bio Q3 2024 Earnings Report

Climb Bio logo
$1.29 +0.09 (+7.50%)
As of 05/16/2025 04:00 PM Eastern

Climb Bio EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Climb Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Climb Bio Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Climb Bio's Q2 2025 earnings is scheduled for Wednesday, May 21, 2025

Climb Bio Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board
See More Climb Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email.

About Climb Bio

Climb Bio (NASDAQ:CLYM) Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

View Climb Bio Profile

More Earnings Resources from MarketBeat